Drug
Immunotoxin HA22 clinical trials
Also written Moxetumomab Pasudotox and CAT-8015.
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
12 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 2007 | 6 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 5
MedImmune LLC (7) · Cambridge Antibody Technology (3) · M.D. Anderson Cancer Center (1) · Center for International Blood and Marrow Transplant Research (1)
Often tested with
Tested in the same studies.
Immunotoxin Therapy (1)
Studies
Open first, then newest update. How each study uses immunotoxin HA22 is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedPhase 1M.D. Anderson Cancer CenterNCT01891981Written as Moxetumomab Pasudotox
- Moxetumomab Pasudotox for Advanced Hairy Cell LeukemiaCompletedPhase 3MedImmune LLCNCT01829711Written as Moxetumomab pasudotox
- A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell LeukemiaCompletedPhase 1MedImmune LLCNCT00586924Written as Moxetumomab Pasudotox (CAT 8015)
- Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)CompletedPhase 1/2MedImmune LLCNCT01030536Written as CAT-8015 20 mcg/kg
- CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaCompletedPhase 1MedImmune LLCNCT00659425Written as CAT-8015 (Moxetumomab Pasudotox)
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic LeukemiaTerminatedPhase 1MedImmune LLCNCT00587457Written as CAT-8015 5 mcg/kg
- Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaTerminatedPhase 2MedImmune LLCNCT02227108Written as Moxetumomab Pasudotox
- Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell TransplantationTerminatedPhase 2Center for International Blood and Marrow Transplant ResearchNCT02338050Written as Moxetumomab Pasudotox
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 1MedImmune LLCNCT00587015Written as CAT-8015
- Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance DiseaseStatus unknownPhase 1Cambridge Antibody TechnologyNCT00515892Written as CAT-8015 Immunotoxin
- Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance DiseaseStatus unknownPhase 1Cambridge Antibody TechnologyNCT00462189Written as CAT-8015 Immunotoxin
- Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance DiseaseStatus unknownPhase 1Cambridge Antibody TechnologyNCT00457860Written as CAT-8015 immunotoxin
Given in every arm · 1 — immunotoxin HA22 is usual care beside what is tested
Codes
What other systems call immunotoxin HA22 · ClinicalTrials.gg INT005459
- MeSH (NLM) C541974immunotoxin HA22Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2NDX4B6N8FMOXETUMOMAB PASUDOTOXConfirmed FDA, NLM
- RxNorm 2099295One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C541974 | immunotoxin HA22 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2NDX4B6N8F | MOXETUMOMAB PASUDOTOX | Confirmed FDA, NLM |
| RxNorm | 2099295 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.